1. Scrip
  2. >>Digital Technologies
  3. >>AI

Sanofi Cements Artificial Intelligence Ambitions With OpenAI and Formation Pact

 
• By Kevin Grogan

The French drugmaker’s aim is to become the first pharma company powered by artificial intelligence at scale, and the collaborations keep coming.

Sanofi
• Source: Getty

Every big pharma player is trumpeting its artificial intelligence efforts but Sanofiis doing more deals than most to boost its drug development activities with the use of AI.

The French drugmaker's latest pact, which it describes as "a first collaboration of its kind within the pharma and life sciences industries," sees Sanofi team up with OpenAI, the high-profile firm behind ChatGPT, and the tech-driven pharmaceutical firm Formation Bio

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Digital Technologies

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 
• By Anju Ghangurde

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By Vibha Ravi

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

 
• By Alaric DeArment

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.